-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

Benzinga·07/13/2026 13:07:44
Listen to the news
B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $160.